Supplemental Table 1. Anatomic Outcomes in Eyes with Branch Vein Occlusion after Injection of a Dexamethasone Implant

Patient ID	Age (years)	CST at Baseline (µm)	CST at Week 4 (µm)	Intraretinal fluid at Baseline	Intraretinal fluid at Week 4	RNP at baseline	Edema Duration (months)	Anti-VEGF injections	Months since last injection
B1	87	337	282	Moderate	Mild	Mild	87	3*	2
B2	89	290	241	Mild	Minimal	Mild	89	5	5
B3	76	508	291	Severe	Mild	Moderate	76	7	9
B4	85	682	257	Severe	Mild	Severe	85	2*	6
B5	80	453	379	Moderate	Mild	Mild	80	-*	-*
B6	54	537	337	Severe	Mild	Mild	54	1	9
B7	72	350	286	Mild	None	Mild	72	28	1
B8	68	712	250	Severe	None	-^	68	3	1
B9	59	522	329	Severe	Mild	Mild	59	36	3
B10	66	792	573	Severe	Moderate	Moderate	66	30	3
B11	58	438	373	Severe	Moderate	-^	58	26	1
B12	62	305	298	Mild	Minimal	Moderate	62	13	1
B13	73	225	206	Mild	Minimal	Moderate	73	2	8
B14	73	580	347	Severe	Mild	Severe	72	11	1
B15	70	359	324	Moderate	Minimal	Mild	70	25	11
B16	61	370	233	Moderate	Minimal	Mild	61	2	2
B17	74	517	263	Severe	Minimal	Mild	74	6	2

* Patient received treatment outside Johns Hopkins Hospital, the medical record for which is not available

^ No gradable fluorescein angiogram

Abbreviations: ID = identifier, CST = central subfield thickness, µm = microns, RNP = retinal nonperfusion, VEGF = vascular endothelial growth factor

Supplemental Table 2: Anatomic Outcomes in Eyes with Central Vein Occlusion after Injection of Dexamethasone Implant

Patient ID	Age (years)	CST at Baseline (µm)	CST at Week 4 (µm)	Intraretinal fluid at Baseline	Intraretinal fluid at Week 4	RNP at baseline	Edema Duration (months)	Anti-VEGF injections	Months since last injection
C1	72	251	204	Moderate	None	Moderate	140	26	6
C2	84	692	323	Severe	Mild	Severe	82	39	8
C3	59	405	336	Moderate	None	Mild	39	32	5
C4	90	319	266	Mild	None	Mild	94	29	11
C5	81	704	263	Severe	None	Mild	70	14	2
C6	81	450	244	Moderate	None	Mild	78	2	2
C7	54	617	182	Severe	None	Moderate	46	19	3
C8	66	311	248	Moderate	Minimal	Severe	63	41	2
C9	55	699	287	Severe	None	Mild	2	2	1
C10	78	599	301	Severe	None	Mild	90	37	6
C11	68	398	335	Moderate	Mild	Severe	38	30	1
C12	69	431	309	Moderate	None	Mild	37	18	5
C13	83	777	520	Severe	Moderate	Mild	79	11	24
C14	83	539	435	Severe	Moderate	Moderate	10	4	3
C15	47	455	234	Severe	None	Mild	45	35	2
C16	58	710	263	Severe	None	Mild	43	26	2
C17	59	840	276	Severe	None	Mild	10	9	1
C18	87	765	282	Severe	None	-^	11	-*	4
C19	74	597	285	Moderate	None	Mild	14	9	-*
C20	74	339	281	Moderate	Mild	-^	54	-*	-*
C21	85	941	169	Severe	None	Severe	6	2	2
C22	77	317	254	Moderate	None	Moderate	17	10	4
C23	86	503	354	Severe	Mild	-^	57	2	2

* Based upon history received several injections elsewhere but not documented

^ No gradable fluorescein angiogram

Abbreviations: ID = identifier, CST = central subfield thickness, µm = microns, RNP = retinal nonperfusion, VEGF = vascular endothelial growth factor

Supplemental Table 3. Changes in Vasoactive Protein Levels 4 Weeks After Injection of Dexamethasone Implant in 11 Patients with Macular Edema Due to Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion (BRVO)		
Severe Edema, Complete Response		
B3	> 70 % decrease	Angiopoietin-1, IGFBP-3, PD-ECGF, PDGF-AA
	50 - 70 % decrease	Endostatin, CXCL-4, Thrombospondin-2
	30 - 50 % decrease	Activin-A, Artemin, EG-VEGF, IGFBP-2, Persephin
	10 -30 % decrease	DPP-IV, HB-EGF, HGF, IGFBP-1, Thrombospondin-1, VEGF-A, Angiogenin
	No Change	Angiostatin, Endothelin-1, Pentraxin 3, CXCL-16, TIMP-1
	Undetected	Leptin, Prolactin
	Increase	Angiopoietin-2, MMP-9, PIGF, Serpin E1, Serpin F1, TIMP-4
B4	> 70 % decrease	Activin-A, HB-EGF, HGF, Leptin, MMP-9, CXCL-4
	50 - 70 % decrease	IGFBP-1, VEGF-A
	30 - 50 % decrease	Endostatin, IGFBP-3, Persephin, TIMP-4, IGFBP-2
	10 -30 % decrease	Angiogenin, CXCL-16, Serpin F1
	No Change	DPP-IV, Endothelin-1, TIMP-1
	Undetected	Angiostatin, Pentraxin 3, PD-ECGF, Prolactin, PDGF-AA, Thrombospondin-1, Thrombospondin-2, Angiopoietin-1, PIGF
	Increase	Angiopoietin-2, Artemin, EG-VEGF, Serpin E1
B8	10 -30 % decrease	IGFBP-3, CXCL-16, TIMP-1
	No Change	Endostatin, IGFBP-2, VEGF-A, Angiogenin
	Undetected	Angiopoietin-1, Angiostatin, Artemin, DPP-IV, HGF, Leptin, PD-ECGF, PIGF, Prolactin
	Increase	Activin-A, Endothelin-1, IGFBP-1, MMP-9, CXCL-4, Serpin E1, Angiopoietin-2, EG-VEGF, HB-ECGF, Pentraxin 3, PDGF-AA, Thrombospondin-1, Thrombospondin-2, Persephin, Serpin F1, TIMP-4
B17	50 - 70 % decrease	IGFBP-2
	30 - 50 % decrease	HGF, IGFBP-1, IGFBP-3, Persephin, Serpin F1
	10 -30 % decrease	VEGF-A, CXCL-16
	No Change	Endostatin, Angiogenin, TIMP-1
	Undetected	Angiostatin, Artemin, Endothelin-1, HB-EGF, Leptin, MMP-9, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-1, Thrombospondin-2
	Increase	Angiopoietin-1, Angiopoietin-2, DPP-IV, EG-VEGF, Activin-A
Severe Edema, Partial Response		

B6	50 - 70 % decrease	IGFBP-2, Persephin, CXCL-16
	30 - 50 % decrease	Activin-A, Endostatin, Endothelin-1, IGFBP-3
	10 -30 % decrease	Artemin, EG-VEGF, IGFBP-1, PDGF-AA, Angiogenin, TIMP-1
	No Change	Angiostatin, VEGF-A, Serpin F1
	Undetected	DPP-IV, HB-EGF, HGF, Leptin, MMP-9, PD-ECGF, PIGF, CXCL-4, Prolactin, Serpin E1, TIMP-4, Thrombospondin-1
	Increase	Angiopoietin-1, Angiopoietin-2, Thrombospondin-2, Pentraxin 3
B9	> 70 % decrease	VEGF-A
	50 - 70 % decrease	EG-VEGF
	30 - 50 % decrease	TIMP-1
	10 -30 % decrease	Endostatin, Endothelin-1, IGFBP-2, IGFBP-3
	No Change	Activin-A, Persephin, Angiogenin, CXCL-16, Serpin F1
	Undetected	HB-EGF, HGF, Leptin, MMP-9, Pentraxin 3, PD-ECGF, PDGF-AA, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-2
	Increase	Angiopoietin-1, Angiopoietin-2, Angiostatin, Artemin, CXCL-4, DPP-IV, Thrombospondin-1
B14	Undetected	Angiopoietin-1, Angiopoietin-2, Angiostatin, Artemin, DPP-IV, Endothelin-1, HB-EGF, HGF, IGFBP-1, Leptin, Pentraxin 3, PD-ECGF, PDGF-AA, Persephin, CXCL-4, PIGF, Prolactin, Serpin F1
	Increase	Angiogenin, TIMP-1, TIMP-4, Activin-A, EG-VEGF, Endostatin, IGFBP-2, IGFBP-3, MMP-9, Serpin E1, VEGF-A, CXCL-16, Thrombospondin-1, Thrombospondin-2
Moderate Edema, Partial Response		
B1	> 70 % decrease	Angiostatin, EG-VEGF, MMP-9, Pentraxin 3, PDGF-AA, Persephin
	50 - 70 % decrease	Activin-A, Angiopoietin-2, Artemin, Endostatin, IGFBP-3, VEGF-A
	30 - 50 % decrease	Endothelin-1, HGF, IGFBP-1, IGFBP-2, TIMP-4, PD-ECGF, CXCL-16, Thrombospondin-1, Thrombospondin-2
	10 -30 % decrease	DPP-IV, Serpin F1
	No Change	Angiogenin, TIMP-1
	Undetected	Angiopoietin-1, HB-EGF, Leptin, CXCL-4, PIGF, Prolactin
	Increase	Serpin E1
B15	> 70 % decrease	Artemin
	30 - 50 % decrease	Persephin
	10 -30 % decrease	Endothelin-1, IGFBP-1, Serpin F1
	Undetected	Angiopoietin-1, Angiostatin, DPP-IV, Endostatin, HGF, IGFBP-2, IGFBP-3, Leptin, MMP-9, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Prolactin, Thrombospondin-1,

		Thrombospondin-2, CXCL-16
	Increase	Activin A, Angiopoietin-2, EG-VEGF, Angiogenin, TIMP-1, Serpin E1, TIMP-4, VEGF-A
B16	> 70 % decrease	EG-VEGF, HB-EGF
	50 - 70 % decrease	Angiopoietin-1, Endostatin, IGFBP-2, CXCL-16
	30 - 50 % decrease	Activin-A, HGF, IGFBP-1, IGFBP-3, Persephin
	10 -30 % decrease	DPP-IV, Endothelin-1, VEGF-A, Angiogenin, TIMP-1
	No Change	Artemin
	Undetected	Angiostatin, Leptin, MMP-9, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-1, Thrombospondin-2
	Increase	Angiopoietin-2, Serpin F1
Mild Edema, Complete response		
B2	> 70 % decrease	Angiostatin, HGF, IGFBP-3
	50 - 70 % decrease	Activin-A, Endostatin, Persephin
	30 - 50 % decrease	IGFBP-2, TIMP-4, VEGF-A
	10 -30 % decrease	EG-VEGF, Endothelin, IGFBP-1, Angiogenin, CXCL-16, Serpin F1
	No Change	TIMP-1
	Undetected	Angiopoietin-1, HB-EGF, MMP-9, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Prolactin, Thrombospondin-1, Thrombospondin-2
	Increase	Artemin, DPP-IV, Serpin E1, Angiopoietin-2, Leptin

Abbreviations: IGFBP = insulin-like growth factor binding protein, PD-ECGF = platelet-derived endothelial cell growth factor, PDGF = platelet-derived growth factor, CXCL4 = C-X-C motif ligand 4, EG-VEGF = endocrine gland-vascular endothelial growth factor, DPP-IV = dipeptidyl peptidase-4, HB-EGF = heparin binding-epidermal growth factor, HGF = hepatocyte growth factor, VEGF = vascular endothelial growth factor, CXCL16 = C-X-C motif ligand 16, TIMP = tissue inhibitor of metalloproteinases, MMP = matrix metalloproteinase, PlGF = placental growth factor

Supplemental Table 4. Changes in Vasoactive Protein Levels 4 Weeks After Injection of Dexamethasone Implant in 11 Patients with Macular Edema Due to Central Retinal Vein Occlusion

Central Retinal Vein Occlusion (CRVO)		
Severe Edema, Complete Response		
C5	50 - 70 % decrease	MMP-9, PD-ECGF, PDGF-AA
	30 - 50 % decrease	EG-VEGF, HB-EGF, IGFBP-1, CXCL-4
	10 -30 % decrease	Angiopoietin-2, Angiostatin, DPP-IV, HGF, Pentraxin 3, Serpin F1
	No Change	Activin-A, Angiopoietin-1, Endothelin-1, IGFBP-2, IGFBP-3, Persephin, VEGF-A, Thrombospondin-2, Angiogenin, CXCL-16, TIMP-1
	Undetected	Leptin
	Increase	Artemin, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-1
C7	> 70 % decrease	DPP-IV, HGF, MMP-9
	50 - 70 % decrease	Angiopoietin-1, HB-EGF, IGFBP-3
	30 - 50 % decrease	EG-VEGF, Endostatin, Endothelin-1, IGFBP-1, IGFBP-2
	10 -30 % decrease	Activin-A, Angiopoietin-2, Artemin, PDGF-AA, Persephin, VEGF-A, Angiogenin, CXCL-16, TIMP-1
	No Change	Angiostatin, PD-ECGF, CXCL-4, Serpin F1
	Undetected	Leptin, Thrombospondin-1, Thrombospondin-2
	Increase	PIGF, Prolactin, Serpin E1, TIMP-4, Pentraxin 3
C21	> 70 % decrease	DPP-IV
	50 - 70 % decrease	IGFBP-1
	30 - 50 % decrease	IGFBP-2, IGFBP-3
	10 -30 % decrease	Activin-A, Endostatin, CXCL-16
	No Change	Angiostatin, VEGF-A, Angiogenin, TIMP-1
	Undetected	Angiopoietin-1, Artemin, HB-EGF, HGF, Leptin, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Serpin E1, TIMP-4, Thrombospondin-1, Thrombospondin-2
	Increase	EG-VEGF,Endothelin-1, MMP-9, Persephin, Serpin F1, Angiopoietin-2
Severe Edema, Partial Response		
C2	> 70 % decrease	Thrombospondin-1
	50 - 70 % decrease	HGF, MMP-9, CXCL-16
	10 -30 % decrease	Angiopoietin-2, Endostatin, IGFBP-3
	No Change	EG-VEGF, IGFBP-2, Leptin, Angiogenin, TIMP-1
	Undetected	Angiopoietin-1, HB-EGF, Pentraxin 3, PD-ECGF, PDGF-AA, CXCL-4, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-2
	Increase	DPP-IV, Endothelin-1, IGFBP-1, Persephin, VEGF-A, Artemin, Activin-A, Angiostatin, Serpin F1
C23	> 70 % decrease	EG-VEGF, Endothelin-1, HG-EGF, HGF, IGFBP-1, MMP-9,

		Thrombospondin-1
	50 - 70 % decrease	Activin-A, Endostatin, IGFBP-2, Pentraxin 3, PDGF-AA, CXCL-16
	30 - 50 % decrease	Thrombospondin-2
	10 -30 % decrease	IGFBP-3, Persephin, Angiogenin
	No Change	Angiostatin, VEGF-A, Serpin F1, TIMP-1
	Undetected	Angiopoietin-1, Artemin, DPP-IV, Leptin, PD-ECGF, CXCL-4, Prolactin, Serpin E1, TIMP-4, PIGF
	Increase	Angiopoietin-2
Moderate Edema, Complete Response		
C1	> 70 % decrease	Activin-A, Angiostatin, Endostatin, HGF, Pentraxin 3, Persephin, Thrombospondin-1, Thrombospondin-2, Serpin F1
	50 - 70 % decrease	CXCL-16
	30 - 50 % decrease	IGFBP-2, IGFBP-3
	10 -30 % decrease	Angiopoietin-2, Endothelin-1, IGFBP-1, Leptin, VEGF-A, TIMP-1
	No Change	DPP-IV, PDGF-AA, Angiogenin
	Undetected	Angiopoietin-1, HB-EGF, MMP-9, PD-ECGF, CXCL-4, PIGF, Prolactin, Serpin E1, TIMP-4
	Increase	Artemin
C3	> 70 % decrease	Angiopoietin-1, IGFBP-3, Leptin
	50 - 70 % decrease	Activin-A , Angiostatin, EG-VEGF , HGF, IGFBP-1
	30 - 50 % decrease	DPP-IV, Endostatin, CXCL-4, CXCL-16
	10 -30 % decrease	IGFBP-2 , MMP-9 , Angiogenin
	No Change	PD-ECGF, Thrombospondin-1, TIMP-1
	Undetected	Pentraxin 3, PDGF-AA, Thrombospondin-2
	Increase	Angiopoietin-2, Artemin, Endothelin-1, HB-EGF, Persephin, PIGF, Prolactin, Serpin E1, Serpin F1, TIMP-4, VEGF-A
C6	> 70 % decrease	IGFBP-3, Pentraxin 3, PDGF-AA, Thrombospondin-1, Thrombospondin-2
	50 - 70 % decrease	Angiopoietin-1, Endostatin, HB-EGF, MMP-9, PD-ECGF
	30 - 50 % decrease	EG-VEGF, HGF, IGFBP-2, PIGF, Prolactin, Serpin E1, TIMP-4
	10 -30 % decrease	Angiostatin, IGFBP-2, Pentraxin 3, Persephin, CXCL-16
	No Change	Angiopoietin-1, VEGF-A, Angiogenin, TIMP-1
	Undetected	Leptin
	Increase	Activin-A, Serpin F1
C8	> 70 % decrease	HB-EGF
	50 - 70 % decrease	EG-VEGF, Endostatin, HGF, IGFBP-3, MMP-9, PDGF-AA, Thrombospondin-1
	30 - 50 % decrease	Activin-A, DPP-IV, IGFBP-1, PD-ECGF, CXCL-4, Thrombospondin-2
	10 -30 % decrease	Angiostatin, IGFBP-2, Pentraxin 3, Persephin, CXCL-16
	No Change	Angiopoietin-1, VEGF-A, Angiogenin, TIMP-1

	Undetected	Leptin
	Increase	Angiopoietin-2, Artemin, Endothelin-1, Serpin E1, Serpin F1, PIGF, Prolactin, TIMP-4
C22	50 - 70 % decrease	CXCL-16
	30 - 50 % decrease	Endostatin, IGFBP-1
	10 -30 % decrease	EG-VEGF, IGFBP-2, IGFBP-3
	No Change	Angiostatin, Angiogenin, TIMP-1
	Undetected	Angiopoietin-1, Artemin, DPP-IV, Endothelin-1, HB-EGF, HGF, Leptin, Pentraxin 3, PDGF-AA, PD-ECGF, CXCL-4, PIGF, Prolactin, Serpin E1, TIMP-4, Thrombospondin-1, Thrombospondin-2
	Increase	Activin-A, Angiopoietin-2, MMP-9, VEGF-A, Serpin F1
Mild Edema, Complete response		
C4	> 70 % decrease	Angiopoietin-1, PD-ECGF
	30 - 50 % decrease	Leptin, CXCL-16
	10 -30 % decrease	Angiopoietin-2, Angiostatin, Endostatin, HGF, IGFBP-3, PDGF-AA, Persephin
	No Change	Artemin, IGFBP-2, CXCL-4, TIMP-1
	Increase	DPP-IV, EG-VEGF, Endothelin-1, IGFBP-1, MMP-9, Pentraxin 3, PIGF, Prolactin, Serpin E1, Serpin F1, TIMP-4, Thrombospondin-1, Thrombospondin-2, Activin-A, HB-EGF, VEGF-A

Abbreviations: IGFBP = insulin-like growth factor binding protein, PD-ECGF = platelet-derived endothelial cell growth factor, PDGF = platelet-derived growth factor, CXCL4 = C-X-C motif ligand 4, EG-VEGF = endocrine gland-vascular endothelial growth factor, DPP-IV = dipeptidyl peptidase-4, HB-EGF = heparin binding-epidermal growth factor, HGF = hepatocyte growth factor, VEGF = vascular endothelial growth factor, CXCL16 = C-X-C motif ligand 16, TIMP = tissue inhibitor of metalloproteinases, MMP = matrix metalloproteinase, PlGF = placental growth factor,

Supplemental Table 5. Aqueous Levels of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Before and After Injection of Dexamethasone Implant in Patients with Branch Retinal Vein Occlusion

Subject ID	Disease Duration (months)	Retinal Non-perfusion	Visit	HGF (pg/ml)	VEGF (pg/ml)	CST (µm)	Intra-retinal fluid	BCVA (Letter Score)
B5	41	Mild	Day 0	270	49.7	453	Moderate	60
			WEEK 4 (% change)	215 (-20.4%)	22.5 (-54.7%)	379	Moderate	60
			WEEK 16 (% change)	255 (+18.6%)	15.2 (-32.5%)	330	Moderate	59
B7	34	Mild	DAY 0	99	71.4	350	Mild	60
			WEEK 4 (% change)	284 (+186.9%)	45.0 (-37.0 %)	286	None	64
B10	42	Moderate	DAY 0	400	40.8	792	Severe	49
			WEEK 4 (% change)	144 (-64.0%)	43.7 (+7.1%)	573	Moderate	64
			WEEK 16 (% change)	165 (+14.6%)	65.2 (49.2%)	494	Moderate	62
B11	39	-*	DAY 0	67	20.1	438	Moderate	70
			WEEK 4 (% change)	53 (-20.9%)	16.2 (-19.4%)	373	Moderate	77
B12	25	Moderate	DAY 0	194	140	305	Mild	54
			WEEK 4 (% change)	110 (-43.3%)	36.2 (-74.2%)	298	Minimal	63
			WEEK 16 (% change)	150 (+36.4%)	not detected	310	Mild	70
B13	109	Moderate	DAY 0	247	55.8	225	Mild	65
			WEEK 4 (% change)	179 (-27.5%)	45.6 (-18.3%)	206	Minimal	63

*No gradable FA

Abbreviations: HGF = hepatocyte growth factor, VEGF = vascular endothelial growth factor, CST = center subfield thickness, BCVA = best-corrected visual acuity

Supplemental Table 6. Aqueous Levels of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Before and After Injection of a Dexamethasone Implant in Patients with Central Retinal Vein Occlusion

Subject ID	Disease Duration (months)	Retinal Non-perfusion	Visit	HGF (pg/ml)	VEGF (pg/ml)	CFT (µm)	Intra-retinal fluid	BCVA (Letter Score)
C9	2	Mild	DAY 0	178	88.2	699	Severe	62
			WEEK 4 (% change)	170 (-4.7%)	63.2 (-28.5%)	287	None	76
			WEEK 16 (% change)	200 (+17.6%)	58.9 (-6.9%)	605	Moderate	63
C10	89	Mild	DAY 0	140	54.0	599	Severe	65
			WEEK 4 (% change)	71 (-49.2%)	-^	301	None	67
			WEEK 16 (% change)	112 (+57.7%)	55.2	562	Moderate	60
C11	54	Severe	DAY 0	200	170.6	398	Moderate	54
			WEEK 4 (% change)	173 (-13.7%)	185.7 (-7.6%)	335	Mild	56
			WEEK 16 (% change)	162 (-6.4%)	147.0 (-20.8%)	328	Mild	54
C12	37	Mild	DAY 0	52	48.3	431	Moderate	76
			WEEK 4 (% change)	54 (+4.5%)	15.2 (-68.6%)	309	None	81
			WEEK 16 (% change)	117 (+116.7 %)	15.7 (+3.3%)	285	None	79
C13	20	Mild	DAY 0	194	97.4	777	Severe	77
			WEEK 4 (% change)	67 (-65.3%)	51.6 (-47.0%)	520	Moderate	78
C14	10	Moderate	DAY 0	203	43.0	539	Severe	22
			WEEK 4 (% change)	261 (+28.6%)	124.0 (+187.3%)	435	Moderate	27
			WEEK 16 (% change)	312 (+19.5%)	74.7 (-39.8%)	1146	Severe	30
C15	45	Mild	DAY 0	85	74.7	455	Severe	68
			WEEK 4 (% change)	154 (+80.1%)	47.1 (-36.9%)	234	None	70
			WEEK 16 (% change)	161 (+4.5%)	94.6 (+100.8%)	265	Moderate	84
C16	43	Mild	DAY 0	83	79.3	710	Severe	43
			WEEK 4 (% change)	94 (+13.2%)	47.3 (-40.4%)	263	None	44
			WEEK 16 (% change)	133 (+41.5%)	86.4 (+82.7%)	525	Moderate	47
C17	62	Mild	DAY 0	107	88.0	840	Severe	62
			WEEK 4 (% change)	67 (-37.0%)	172.7 (+96.0%)	276	None	70

			WEEK 16 (% change)	97 (+44.8%)	129.4 (-25.1%)	659	Moderate	60
C18	10	-*	DAY 0	176	148.8	765	Severe	21
			WEEK 4 (% change)	129 (-27.0%)	389.2 (+162.0%)	282	None	31
C19	13	Mild	DAY 0	137	28.6	597	Moderate	59
			WEEK 4 (% change)	85 (-38.3%)	68.8 (+140.6%)	285	None	72
C20	53	-*	DAY 0	196	118.0	339	Moderate	61
			WEEK 4 (% change)	141 (-28.1%)	116.4 (-1.4%)	281	Mild	73

*No gradable FA

^ Not Detectable

Abbreviations: HGF = hepatocyte growth factor, VEGF = vascular endothelial growth factor, CST = center subfield thickness, BCVA = best-corrected visual acuity

Supplemental Figure 1. Foveal horizontal spectral domain-optical coherence tomography scans at each study visit for patients with branch retinal vein occlusion who received a dexamethasone implant.

Horizontal scans through the fovea at each study visit are shown for 17 patients with branch vein occlusion (B1-B17), divided into 4 images: (1) B1-B5, (2) B6-B10, (3) B11-B15, and (4) B16-B17. Visits at which a dexamethasone implant was injected are indicated by Dex in the lower right of the box and visits at which an anti-vascular endothelial growth factor (anti-VEGF) injection was given are indicated by anti-VEGF in the lower right of the box. The central subfield thickness is shown in the upper left and the best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letter score is shown in the upper right of each box. Blank boxes indicate a missed visit.

Supplemental Figure 2. Foveal horizontal spectral domain-optical coherence tomography scans at each study visit for patients with central retinal vein occlusion who received a dexamethasone implant.

Horizontal scans through the fovea at each study visit are shown for 23 patients with central vein occlusion (C1-C23), divided into 5 images: (1) C1-C5, (2) C6-B10, (3) C11- C15, and (4) C16- C20, and (5) C21-C23. Visits at which a dexamethasone implant was injected are indicated by Dex in the lower right of the box and visits at which an anti-vascular endothelial growth factor (anti-VEGF) injection was given are indicated by anti-VEGF in the lower right of the box. The central subfield thickness is shown in the upper left and the best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letter score is shown in the upper right of each box. Blank boxes indicate a missed visit.


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
B1
B2
B3
B4
B5
337 38
282 37
271 37
254 38
480 38
290 64
241 56
240 59
235 61
273 68
508 29
291 34
272 32
263 25
300 23
682 27
257 52
453 60
379 60
359 58
505 53
330 59
Dex


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
B6
537
71
337
70
313
75
506
67
589
68
Dex
Dex
B7
350
60
286
64
Dex
B8
712
68
250
78
248
79
327
84
249
85
Dex
Dex
B9
522
65
329
63
280
80
280
79
495
78
Dex
B10
792
49
573
64
698
59
591
62
494
62
Dex
Dex


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
B11
438 70
Dex
373 77
356 82
528 80
B12
305 54
Dex
298 63
295 58
297 65
310 70
B13
225 65
Dex
206 63
209 57
222 65
B14
580 29
Dex
347 40
348 35
333 37
755 42
B15
359 42
Dex
324 51
316 50
352 50
Anti-VEGF
328 59


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
B16
370
65
Dex
233
70
231
66
537
65
B17
517
64
Dex
263
74
259
75
451
55
Dex
257
89


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
C1
C2
C3
C4
C5
251 69 Dex
204 62
200 66
191 59
200 69
692 20 Dex
323 22
278 30
329 30
611 50 Dex
405 55 Dex
336 55
312 55
372 58
412 59
319 25 Dex
266 31
259 31
284 37
276 34
704 35 Dex
263 35
251 38
259 33
310 32


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
C6
C7
C8
C9
C10
450 52
244 59
240 61
255 61
279 50
617 43
182 54
180 63
302 53
553 54
311 41
248 45
245 48
259 47
286 47
699 62
287 76
291 69
480 62
605 63
599 65
301 67
307 69
312 74
562 60
Dex
Anti-VEGF


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
C11
C12
C13
C14
C15
398
54
Dex
335
56
328
55
364
55
Dex
328
54
431
76
Dex
309
81
284
75
321
63
Anti-VEGF
285
79
777
20
Dex
520
25
539
22
Dex
435
27
415
25
413
28
1146
30
Dex
455
68
Dex
234
70
228
79
227
81
265
84


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
C16
C17
C18
C19
C20
710 58 Dex
263 78
252 70
325 68
525 56
840 62 Dex
276 70
259 75
362 65
659 60
765 21 Dex
282 31
269 32
587 20 Dex
212 24
597 59 Dex
285 72
273 77
789 56 Dex
288 71
339 61 Dex
281 74
275 74
278 75
340 73


BASELINE
WEEK 4
WEEK 8
WEEK 12
WEEK 16
C21
C22
C23
941
19
169
29
169
25
173
27
196
10
317
48
254
52
235
46
226
38
261
41
503
54
354
51
301
50
511
50
419
50
Dex
Dex
Dex